Eltanexor clinical trials
Also written KPT-8602 and ATG-016.
How each study uses Eltanexor is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Eltanexor studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
Shanghai Antengene Corporation Limited (2) · Karyopharm Therapeutics Inc (1) · Vanderbilt-Ingram Cancer Center (1) · National Cancer Institute (NCI) (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Eltanexor.
- Feb 2027Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid LeukemiaPhase 1 · Vanderbilt-Ingram Cancer Center
Studies
Open first, then newest update. How each study uses Eltanexor is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid LeukemiaRecruitingPhase 1Vanderbilt-Ingram Cancer CenterNCT06399640Written as EltanexorHow we know
- Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic SyndromesTerminatedPhase 1/2National Cancer Institute (NCI)NCT05918055Written as KPT-8602How we know
- Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer IndicationsCompletedPhase 1/2Karyopharm Therapeutics IncNCT02649790Written as KPT-8602How we know
- A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS)TerminatedPhase 1/2Shanghai Antengene Corporation LimitedNCT04691141Written as ATG-016How we know
- A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid TumorsTerminatedPhase 1/2Shanghai Antengene Corporation LimitedNCT05010525Written as ATG-016How we know
Codes
What other systems call Eltanexor · ClinicalTrials.gg INT001866
- MeSH (NLM) C000722651EltanexorOne source ClinicalTrials.gov
- UNII (FDA) Q59IQJ9NTKELTANEXOROne source FDA
- NCI Thesaurus C125193EltanexorOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722651 | Eltanexor | One source ClinicalTrials.gov |
| UNII (FDA) | Q59IQJ9NTK | ELTANEXOR | One source FDA |
| NCI Thesaurus | C125193 | Eltanexor | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.